Immunotherapy in fungal allergy

Area of Science:

• Allergen immunotherapy
• Respiratory allergy
• Fungal allergy

Background:

• Airborne fungal spores are a known cause of respiratory allergies, particularly severe asthma in young adults.
• Sensitization rates to fungal allergens can be high (up to 30%) in asthma patients, despite a general prevalence of around 3% in the population.
• Currently available commercial fungal extracts for diagnosis and therapy are often of poor quality, limiting effective treatment.

Purpose of the Study:

• To highlight the challenges in diagnosing and treating fungal allergies due to extract quality.
• To review the efficacy of current immunotherapy for fungal allergies.
• To explore the potential of recombinant fungal allergens for future diagnosis and immunotherapy.

Main Methods:

• Review of existing literature on fungal allergy, sensitization, and immunotherapy.
• Analysis of clinical trial data for immunotherapy efficacy.
• Discussion of the limitations of current diagnostic and therapeutic approaches.

Main Results:

• Limited efficacy of immunotherapy has been demonstrated for only two fungal species (Alternaria alternata and Cladosporium herbarum) in controlled trials.
• The quality of commercial fungal extracts remains a significant barrier to accurate diagnosis and effective treatment.
• Recombinant fungal allergens present a promising avenue for advancing diagnosis and immunotherapy.

Conclusions:

• Current methods for diagnosing and treating fungal allergies are suboptimal due to issues with fungal extract quality.
• Specific immunotherapy has shown promise but is limited to a few fungal species.
• Recombinant fungal allergens represent a significant advancement for the future of fungal allergy management.